WO2008110941A2 - New process of synthesis of a squalamine and/or trodusquemine precursor - Google Patents
New process of synthesis of a squalamine and/or trodusquemine precursor Download PDFInfo
- Publication number
- WO2008110941A2 WO2008110941A2 PCT/IB2008/001730 IB2008001730W WO2008110941A2 WO 2008110941 A2 WO2008110941 A2 WO 2008110941A2 IB 2008001730 W IB2008001730 W IB 2008001730W WO 2008110941 A2 WO2008110941 A2 WO 2008110941A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- anyone
- synthesis according
- derivative
- preferentially
- Prior art date
Links
- 0 C[C@](CC1)(C(CC2)C(CC3)C1[C@]1(C)C3CC(*)CC1)C2=C(C)* Chemical compound C[C@](CC1)(C(CC2)C(CC3)C1[C@]1(C)C3CC(*)CC1)C2=C(C)* 0.000 description 8
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0003—Androstane derivatives
- C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
- C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/0015—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa
- C07J7/002—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group not substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
Definitions
- the invention relates to a new process of synthesis of a squalamine and/or trodusquemine precursor.
- squalamine and trodusquemine belong to a novel class of water soluble cationic steroids and are the first example of natural products which are adducts of a polyamine and a sterol. These compounds display potent antifungal and antibacterial activities against various yeasts and both Gram negative and Gram positive bacteria. However the most significant property is their antiangiogenic activity which led to their development for cancer chemotherapy in the treatment of late stage lung cancer and ovarian cancer. At present the feasibility of obtaining large quantities of steroidal antibiotic from natural sources appears questionable since only trace amounts of squalamine and trodusquemine are present in the liver and gallbladder of the shark.
- the stereoselective controlled synthesis of the lateral chain group and its introduction on a sterol moiety constitutes the innovative and new step of the process of the invention.
- an alkyl group a carbon radical with 1 to 24 carbon atoms, either linear or branched, possibly substituted with a halogen atom, a hydroxyl radical, an amino group, a carboxylic acid group.
- an either linear or branched carbon radical having 1 to 6 carbon atoms is meant a radical selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl radicals.
- a preferred alkyl group is a methyl radical; - an aryl group, a radical derived from a monocyclic or polycyclic aromatic group having from 6 to 10 carbon atoms, optionally substituted with one or more substituents.
- the substituants may be selected from a halogen atom, an alkyl group, either linear or branched, having from 1 to 4 carbon atoms, optionally substituted with one or more halogen atoms, with a hydroxyl group, with an amino group, or with an alkoxy group having from 1 to 3 carbon atoms, a hydroxyl group, a nitro group, a cyano group, a 1 ,3-dioxolyl group, a carbonyl group, a methylsulfonyl group or an amino group optionally mono-or di- substituted with an alkyl group having from 1 to 3 carbon atoms; preferentially according to the invention, the aryl group is a phenyl group optionally substituted as defined above;
- the invention relates to an innovative process of synthesis of 24-substituted oxy-7-substitutedoxycholestan-3-one of formula I
- R1 and R2 can be, simultaneously or independently, an alkyl, aryl, ester, ether, silyl, substituted silyl, sulfate or phosphate group, process in which in ⁇ step A, one prepares an oxy disubstituted derivative of formula Il
- R3 represents an ester or an ether group
- R4 represents a vinyl group, methylallyl group or a diethylphosphonium group of formula Ma, lib or MC
- R5, R6, R7 and R8 represent an alkyl, aryl, halide or amine group ⁇ step B, one prepares a 3-siloxy-18-trifluoromethanesulfonyloxy dehydroepiandrosterone derivatives of formula III
- R9, R10 and R11 different or identical, represent a linear or branched alkyl or ether radical, with 1 to 24 carbons, preferentially with 1 to 4 carbons, or an aryl radical (phenyl or substituted phenyl group); or a 3-substituted oxy pregnenolone of formula V, or a 3-substituted oxy-7-oxy pregnane derivatives of formula Vl or VII.
- a first catalyst made of a mixture of Palladium acetate [Pd(OAc) 2 ] or Palladium salt like Pd(OAc) 2 and a first ligand like a phosphine, for example triphenylphosphine, tributylphosphine, tri te/f-butyl phosphine and preferentially tri-OA#7o-tolylphosphine, under inert atmosphere like argon or nitrogen, in a first polar solvent like dimethylformamide (DMF) or dimethylacetamide or hexamethylphosphoramide (HMPA), and in the presence of a first base, which can be an aromatic amine like triethylamine or pyridine at a temperature comprised between 50 0 C to 70 0 C, preferentially 60 0 C,
- step B by reacting the substited oxy derivative Hc obtained in step A with the pregnane derivatives (formula V-VII) obtained in step B, in the presence of a second base like sodium hydride, lithium hexamethyldisilazane, butyllithium, sec- butyllithium or tert-butyllithium, preferentially sodium hydride under inert atmosphere like argon or nitrogen, in a second polar solvent like THF at a temperature comprised between 0 to 25°C, preferentially O 0 C, during 1 to 24 hours, preferably 12 hours, the expected compound being eventually purified;
- a second base like sodium hydride, lithium hexamethyldisilazane, butyllithium, sec- butyllithium or tert-butyllithium, preferentially sodium hydride under inert atmosphere like argon or nitrogen, in a second polar solvent like THF at a temperature comprised between 0 to 25°C, prefer
- step D one prepares a 3-siloxy-24-substituted oxy-7 one pregnane derivatives of formula XIII or XIV or a 3-substituted-24-substituted oxy-7 one pregnane derivatives of Formula Xl
- step C by oxidizing derivatives of formula VIII or X obtained in step C, the expected compound being eventually purified;
- step E one prepares a 3-substituted oxy-24-substituted 7-one derivative of formula XV
- a catalyst preferentially platinum oxide catalyst, under hydrogen, at a pressure comprised between 1 to 100 bars, preferably 3 bars, during 1 to 30 hours, preferably 24 hours, preferably at 25 0 C, in a polar solvent like DMF, dimethylacetamide, THF, dioxame or hexamethylphosphoramide (HPMA), the expected compound being eventually purified;
- a catalyst preferentially platinum oxide catalyst, under hydrogen, at a pressure comprised between 1 to 100 bars, preferably 3 bars, during 1 to 30 hours, preferably 24 hours, preferably at 25 0 C, in a polar solvent like DMF, dimethylacetamide, THF, dioxame or hexamethylphosphoramide (HPMA), the expected compound being eventually purified;
- step F one prepares a 24-substituted oxy-3-hydroxycholestan-7-one derivative of formula XVI
- step E by deprotection of the 3-substituted-24-substituted-7-one derivative of formula XV obtained in step E preferentially in presence of a fluorhydric acid- based reagent (HF-based reagent), the expected compound being eventually purified;
- a fluorhydric acid- based reagent HF-based reagent
- step G one prepares a 24-substituted oxy-3,7-dihydroxycholestane derivative of formula XVII
- step F by the reduction of the ketone in position 7 of the 24-substituted-3- hydroxycholestan-7-one derivative of formula XVI obtained in step F with a stereoselective reducing hydride reagent, preferentially
- step H one prepares the 24-substituted oxy-7-hydroxycholestan-3-one of formula I by oxidation of the hydroxyl substituant in position 3 of the 24- substituted-3,7-dihydroxycholestane derivative of formula XVII obtained in step G, in presence of silver carbonate in a solvent preferentially like toluene, benzene, hexane, heptane or cyclohexane, at the reflux temperature of the solvent, the expected compound being eventually purified.
- a solvent preferentially like toluene, benzene, hexane, heptane or cyclohexane at the reflux temperature of the solvent, the expected compound being eventually purified.
- the process renders possible the synthesis of 3, 7 and/or 24 ⁇ or ⁇ substituted compounds.
- the process of the invention is used to prepare 3 ⁇ , 24 ⁇ and 7 ⁇ substituted compounds.
- one of the aims of the present invention is to propose a stereoselective preparation of 24 ⁇ -benzoyloxy-7 ⁇ - hydroxycholestan-3-one key intermediate valuable for the total synthesis of squalamine or trodusquemine implying the use of easily available cheaper starting material as for example pregnelone.
- the stereoselective controlled synthesis of the lateral chain group and its introduction on a sterol moiety constitutes the key step of the process of the invention.
- the invention relates to a new process of synthesis of 24 ⁇ - benzoyloxy-7 ⁇ -hydroxycholestan-3-one of formula I'
- R4 represents a vinyl group or a methylallyl group
- step B one prepares a 3 ⁇ -siloxy-18- trifluoromethanesulfonyloxydehydroepiandrosterone derivatives of formula III
- R9, R10 and R11 different or identical, represent a linear or branched alkyl radical, with 1 to 24 carbons, preferentially with 1 to 4 carbons, or an aryl radical (phenyl or substituted phenyl group);
- step A by reacting the benzoate derivative obtained in step A with the 3 ⁇ -siloxy-20- trifluoromethanesulfonyloxy pregnenane derivative (formula IV) or a 3 ⁇ -siloxy-18- trifluoromethanesulfonyloxy dehydroepiandrosterone derivative (formula III) obtained in step B, in the presence of a first catalyst made of a mixture of Palladium acetate [Pd(OAc) 2 ] or Palladium salt like Pd(OAc) 2 and a first ligand which can be a phosphine ligand like triphenylphosphine, tributylphosphine, tri te/f-butyl phosphine and preferentially tri-o/t/70-tolylphosphine in a 1 :2 P/Ligand ratio, under inert atmosphere like argon or nitrogen, in a first polar solvent like DMF or dimethylacetamide,
- step D one prepares a 3 ⁇ -siloxy-24 ⁇ -benzoyloxy-5, 20, 22 triene- hydroxycholestane-7-one derivative of formula XIII 1
- step E one prepares a 3 ⁇ -siloxy-24 ⁇ -benzoyloxy-7-one derivative of formula XV
- step D by hydrogenation of the 3 ⁇ -siloxy-24 ⁇ -benzoyloxy-5, 20, 22 triene- hydroxycholestane-7-one derivative of formula VIM' obtained in step D, in the presence of platinum oxide under hydrogen under pressure, during 1 to 30 hours, preferably 24 hours, at a temperature comprised between 20 to 30 0 C, preferably 25°C, in a solvent indifferently chosen as ethyl acetate or ethanol, the expected compound being eventually purified;
- step F one prepares a 24 ⁇ -benzoyloxy-3 ⁇ -hydroxycholestan-7-one derivative of formula XVI 1
- step E by deprotection of the 3 ⁇ -siloxy-24 ⁇ -benzoyloxy-7-one derivative of formula XV obtained in step E in presence of a fluorhydric acid-based reagent (HF-based reagent), the expected compound being eventually purified;
- HF-based reagent fluorhydric acid-based reagent
- step G one prepares a 24 ⁇ -benzoyloxy-3 ⁇ ,7 ⁇ -dihydroxycholestane derivative of formula XVIII 1
- step H one prepares the 24-benzoyloxy-7 ⁇ -hydroxycholestan-3-one of formula I' by oxidation of the hydroxyl substituent in position 3 of the 24 ⁇ - benzoyloxy-3 ⁇ ,7 ⁇ -dihydroxycholestane derivative of formula XVIII' obtained in step G, in presence of silver carbonate in an aromatic solvent like toluene, at the reflux temperature of the solvent during 24 hours, the expected compound being eventually purified.
- the chiral derivative of formula Il may be prepared by any well known processes, as for example according to the method describes by Enders et al. (Enders, D. Synlett 1994, 969).
- the compound of Formula Il is a benzoate derivative, obtained by reacting an hydroxyl derivative of formula XVIII.
- R13 represents a vinyl, a methylallyl or an halogeno ethyl group with benzoylchloride in the presence of a base at temperature growing from O 0 C to 25°C during a minimum of 24 hours, the expected compound being eventually purified.
- step B of the invention the 3-siloxy-20- trifluoromethanesulfonyloxy pregnane of formula IV
- R9, R10 and R11 different or identical, represent a linear, branched alkyl or ether radical, with 1 to 24 carbons, preferentially with 1 to 4 carbons, or an aryl radical (phenyl or substituted phenyl group), under inert atmosphere like argon or nitrogen, in the presence of a solvent chosen indifferently from tetrahydrofuran (THF) or other ethers, dichloromethane (CH2CI2) or chloroform (CHCI 3 ) or other chlorinated solvent, or dimethylformamide (DMF) or acetonitrile (CH 3 CN) or toluene or benzene in the presence of a base like pyridine or triethylamine , at a temperature between 20 to 50 0 C, during 20 to 30 hours, preferentially in presence of DMF at 25 0 C for 24 hours, the expected compound being eventually purified; and in which R9, R10 and R11 , different or identical, represent a linear, branched
- step B1-2 one prepares the 3-siloxy-20-trifluoromethanesulfonyloxy pregnenolone derivatives of formula IV by reacting the 3-siloxypregnenolone derivative of formula XIX obtained in step B1-1 with potassium bis(trimethylsilyl)amide in toluene (5 to 15 %, preferentially 10%) and N- phenyltrifluoromethanesulfonimide in THF, under inert atmosphere like argon, at a temperature comprised between-80°C to-70°C, preferentially-78°C, during 15 to 45 minutes, and then warmed to a temperature around 0 0 C, the expected compound being eventually purified.
- potassium bis(trimethylsilyl)amide in toluene 5 to 15 %, preferentially 10%
- N- phenyltrifluoromethanesulfonimide in THF, under inert atmosphere like argon, at a temperature comprised between-80°C to-
- step B of the invention the 3-siloxy-18- trifluoromethanesulfonyloxy dehydroepiandrosterone derivatives of formula
- step B2-1 one prepares a 3-siloxydehydroepiandrosterone derivative of formula XXI
- R9, R10 and R11 different or identical, represent a linear, branched alkyl or ether radical, with 1 to 24 carbons, preferentially with 1 to 4 carbons, or an aryl radical (phenyl or substituted phenyl group), under inert atmosphere like argon or nitrogen, in the presence of a solvent chosen indifferently from tetrahydrofuran (THF) or other ethers, dichloromethane (CH 2 CI 2 ) or chloroform (CHCI 3 ) or other chlorinated solvent, or dimethylformamide (DMF) or acetonitrile (CH 3 CN) or toluene or benzene in the presence of a base like pyridine or triethylamine , at a temperature between 20 to 50 0 C, during 20 to 30 hours, preferentially in presence of DMF at 25°C for 24 hours, the expected compound being eventually purified; and in which R9, R10 and R11 , different or identical, represent a linear,
- step B2-2 one prepares the 3-siloxy-18-trifluoromethanesulfonyloxy dehydroepiandrosterone derivative of formula III
- step B2-1 by reacting the 3-siloxydehydroepiandrosterone derivative of formula XXI obtained in step B2-1 with potassium bis(trimethylsilyl)amide in toluene (5 to 15 %, preferentially 10%) and N-phenyltrifluoromethanesulfonimide in THF, under inert atmosphere like argon, at a temperature comprised between-80°C to-70°C, preferentially-78°C, during 15 to 45 minutes, and then warmed to a temperature around 0 0 C, the expected compound being eventually purified.
- potassium bis(trimethylsilyl)amide in toluene 5 to 15 %, preferentially 10%
- N-phenyltrifluoromethanesulfonimide in THF, under inert atmosphere like argon, at a temperature comprised between-80°C to-70°C, preferentially-78°C, during 15 to 45 minutes, and then warmed to a temperature around 0 0 C, the
- the expected compound is preferentially purified according to well known methods.
- the compounds may be purified by chromatography, for example on a silicagel column or by crystallization.
- the oxidation may be performed by well known methods.
- the oxidation may be performed for example in the presence of ruthenium trichloride and tert- butylhydroperoxide in cyclohexane, during 20 to 30 hours, preferentially 24 hours, at a temperature comprised between 20 to 30 0 C, preferentially 25 0 C.
- the oxidation of step D may be performed for example in the presence of Na 2 Cr 2 O 7 in acetone, during 45 to 50 hours, preferentially 48 hours, at a temperature comprised between 35 to 45°C, preferentially 40 0 C, in the presence of sodium sulfite.
- the oxidation of step D may be performed in the presence of N-hydroxyphtalamide, under a flux of oxygen or air, in the a 50/50 solvent mixture of ethylacetate and acetone, at 60 0 C, during 30 to 40 hours, preferentially 36 hours.
- the deprotection may be performed in the presence of a fluorhydric acid-based reagent (HF-based reagent), in a solvent chosen from tetrahydrofuran (THF) or other ethers, dichloromethane (CH 2 CI 2 ) or Chloroform (CHCI 3 ) or other chlorinated solvent, or acetonitrile (CH 3 CN) or ethyl acetate or diethylether, at temperature raising from-85°C to-65°C, preferentially-78°C, to 25 0 C during a time comprised between 30 to 60 minutes, preferentially 45 minutes.
- a fluorhydric acid-based reagent HF-based reagent
- a solvent chosen from tetrahydrofuran (THF) or other ethers, dichloromethane (CH 2 CI 2 ) or Chloroform (CHCI 3 ) or other chlorinated solvent, or acetonitrile (CH 3 CN) or e
- HF-based reagent may be chosen from tetrabutylammoniumfluoride (Bu 4 )N, tetraalkylarylammoniumfluoride derivative or polymer-bound ammonium fluoride salt, preferentially the HF-based reagent is tetrabutylammoniumfluoride (Bu 4 )N.
- Example 1 Example of step B of the invention
- reaction mixture is warmed to 0 0 C, stirred at this temperature for additionnal 15 minutes, poured on buffer pH 7 and then extracted three times with Et 2 O.
- the combined ether phases are dried over sodium sulfate, filtered, evaporated to dryness and purified by chromatography on silicagel (eluent: petroleum ether/ethylacetate 97/3) affording the expected compound of formula XXIV as a white solid in 46% yield (133 mg).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Steroid Compounds (AREA)
Abstract
The invention relates to a new process of synthesis of a squalamine and/or trodusquemine precursor like 24-substituted oxy-7-substitutedoxycholestan-3- one, preferably of 24β-benzoyloxy-7α-hydroxycholestan-3-one.
Description
New process of synthesis of a squalamine and/or trodusquemine precursor
The invention relates to a new process of synthesis of a squalamine and/or trodusquemine precursor.
Issued from the tissues of dogfish shark Squalus Acanthias, squalamine and trodusquemine belong to a novel class of water soluble cationic steroids and are the first example of natural products which are adducts of a polyamine and a sterol. These compounds display potent antifungal and antibacterial activities against various yeasts and both Gram negative and Gram positive bacteria. However the most significant property is their antiangiogenic activity which led to their development for cancer chemotherapy in the treatment of late stage lung cancer and ovarian cancer. At present the feasibility of obtaining large quantities of steroidal antibiotic from natural sources appears questionable since only trace amounts of squalamine and trodusquemine are present in the liver and gallbladder of the shark.
To date several synthetic routes have been established to prepare these compounds on a large scale to supply them for clinical trials.
Thus, the first synthesis of squalamine has been performed in 1994 by Moriarty et al. from 3β-acetoxy-5-cholenic acid in a 17 steps sequence and 0.3% overall yield epimeric in C-24.
In 2000, Kinney et al. (Kinney, W. A.; Jones, S.; Zhang, X.; Rao, M. N.; Bulliard, M.; Meckler, H.; Lee, N. In PCT Int. Appl.; (Magainin Pharmaceuticals Inc., USA).
Wo, 1998, p 116 pp. and Kinney, W. A.; Zhang, X.; Williams, J. I.; Johnston, S.;
Michalak, R. S.; Deshpande, M.; Dostal, L.; Rosazza, J. P. N. Organic Letters
2000, 2, 2921-2922.) reported a ten steps preparation of squalamine from 3-keto- 23,24-bisnorchol-4-en-22-ol in 9% overall yield and 91% diastereomeric excess (de).
More recently, Zhou et al. (Zhou, X. D.; CaI, F.; Zhou, W. S. Tetrahedron Letters
2001, 42, 2537-2539 and Zhou, X.-D.; Cai, F.; Zhou, W.-S. Tetrahedron 2002, 58, 10293-10299) have described a stereoselective construction of squalamine
sidechain by using methyl-S-keto-δα-chenodeoxycholanate as starting material. This short route to squalamine was achieved in eleven steps with an overall yield of 19% and 99% de but the starting material involved in this synthesis remains still expensive. It is one of the aims of the present invention to propose a stereoselective preparation of 24-benzoyloxy-7-hydroxycholestan-3-one, preferentially 24- benzoyloxy-7a-hydroxycholestan-3-one, key intermediate valuable for the total synthesis of squalamine or trodusquemine using of commercially available inexpensive starting material as for example pregnelone. The stereoselective controlled synthesis of the lateral chain group and its introduction on a sterol moiety constitutes the innovative and new step of the process of the invention.
According to the invention, is meant by :
- an alkyl group, a carbon radical with 1 to 24 carbon atoms, either linear or branched, possibly substituted with a halogen atom, a hydroxyl radical, an amino group, a carboxylic acid group. By an either linear or branched carbon radical having 1 to 6 carbon atoms, is meant a radical selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl radicals. According to the invention, a preferred alkyl group is a methyl radical; - an aryl group, a radical derived from a monocyclic or polycyclic aromatic group having from 6 to 10 carbon atoms, optionally substituted with one or more substituents. The substituants may be selected from a halogen atom, an alkyl group, either linear or branched, having from 1 to 4 carbon atoms, optionally substituted with one or more halogen atoms, with a hydroxyl group, with an amino group, or with an alkoxy group having from 1 to 3 carbon atoms, a hydroxyl group, a nitro group, a cyano group, a 1 ,3-dioxolyl group, a carbonyl group, a methylsulfonyl group or an amino group optionally mono-or di- substituted with an alkyl group having from 1 to 3 carbon atoms; preferentially according to the invention, the aryl group is a phenyl group optionally substituted as defined above;
The invention relates to an innovative process of synthesis of 24-substituted oxy-7-substitutedoxycholestan-3-one of formula I
wherein R1 and R2 can be, simultaneously or independently, an alkyl, aryl, ester, ether, silyl, substituted silyl, sulfate or phosphate group, process in which in ❖ step A, one prepares an oxy disubstituted derivative of formula Il
OR3
R7 Formula II
wherein
R3 represents an ester or an ether group
R4 represents a vinyl group, methylallyl group or a diethylphosphonium group of formula Ma, lib or MC
R5, R6, R7 and R8 represent an alkyl, aryl, halide or amine group ❖ step B, one prepares a 3-siloxy-18-trifluoromethanesulfonyloxy
dehydroepiandrosterone derivatives of formula III
OTf
Formula III or a 3-siloxy-20-trifluoromethanesulfonyloxy pregnane derivative of formula
IV
Formula IV in which R9, R10 and R11, different or identical, represent a linear or branched alkyl or ether radical, with 1 to 24 carbons, preferentially with 1 to 4 carbons, or an aryl radical (phenyl or substituted phenyl group); or a 3-substituted oxy pregnenolone of formula V, or a 3-substituted oxy-7-oxy pregnane derivatives of formula Vl or VII.
Formula V
Formula VI
Formula VII
wherein R represents an ether, silyl, substituted silyl or ester group; ❖ step C, one prepares a pregnane derivative of formula VIII or IX
by reacting the substited oxy derivative Hc obtained in step A with the pregnane derivatives (formula V-VII) obtained in step B, in the presence of a second base like sodium hydride, lithium hexamethyldisilazane, butyllithium, sec- butyllithium or tert-butyllithium, preferentially sodium hydride under inert atmosphere like argon or nitrogen, in a second polar solvent like THF at a temperature comprised between 0 to 25°C, preferentially O0C, during 1 to 24 hours, preferably 12 hours, the expected compound being eventually purified;
❖ step D, one prepares a 3-siloxy-24-substituted oxy-7 one pregnane derivatives of formula XIII or XIV or a 3-substituted-24-substituted oxy-7 one pregnane derivatives of Formula Xl
by oxidizing derivatives of formula VIII or X obtained in step C, the expected compound being eventually purified;
❖ step E, one prepares a 3-substituted oxy-24-substituted 7-one derivative of formula XV
❖ step F, one prepares a 24-substituted oxy-3-hydroxycholestan-7-one derivative of formula XVI
❖ step G, one prepares a 24-substituted oxy-3,7-dihydroxycholestane derivative of formula XVII
- in the presence of potassium tri-sec-butylborohydride (L-selectride®) to obtain a 7α dihydrocholestane - or Iithium/NH3 to obtain a 7βdihydrocholestane at a temperature raising from-78°C to room temperature (25°C), the expected compound being eventually purified;
❖ step H, one prepares the 24-substituted oxy-7-hydroxycholestan-3-one of formula I by oxidation of the hydroxyl substituant in position 3 of the 24- substituted-3,7-dihydroxycholestane derivative of formula XVII obtained in step G, in presence of silver carbonate in a solvent preferentially like toluene, benzene, hexane, heptane or cyclohexane, at the reflux temperature of the solvent, the expected compound being eventually purified.
According to the invention, the process renders possible the synthesis of 3, 7 and/or 24 α or β substituted compounds. Preferentially the process of the invention is used to prepare 3β, 24β and 7α substituted compounds.
For example, in one preferred embodiment, one of the aims of the present invention is to propose a stereoselective preparation of 24β-benzoyloxy-7α- hydroxycholestan-3-one key intermediate valuable for the total synthesis of squalamine or trodusquemine implying the use of easily available cheaper starting material as for example pregnelone.
Contrarily to all the other reported methods, the stereoselective controlled synthesis of the lateral chain group and its introduction on a sterol moiety constitutes the key step of the process of the invention. Thus, the invention relates to a new process of synthesis of 24β- benzoyloxy-7α-hydroxycholestan-3-one of formula I'
❖ step A, one prepares a benzoate derivative of formula Il
OCOPh
❖ step B, one prepares a 3β-siloxy-18- trifluoromethanesulfonyloxydehydroepiandrosterone derivatives of formula III
❖ step C, one prepares a 3β-siloxy-24β-benzoyloxy-5,20,22 triene- hydroxycholestane derivative of formula VIII1
by reacting the benzoate derivative obtained in step A with the 3β-siloxy-20- trifluoromethanesulfonyloxy pregnenane derivative (formula IV) or a 3β-siloxy-18- trifluoromethanesulfonyloxy dehydroepiandrosterone derivative (formula III) obtained in step B, in the presence of a first catalyst made of a mixture of Palladium acetate [Pd(OAc)2] or Palladium salt like Pd(OAc)2 and a first ligand which can be a phosphine ligand like triphenylphosphine, tributylphosphine, tri te/f-butyl phosphine and preferentially tri-o/t/70-tolylphosphine in a 1 :2 P/Ligand ratio, under inert atmosphere like argon or nitrogen, in a first polar solvent like DMF or dimethylacetamide, and a first base like triethylamine or pyridine at a temperature comprised between 500C to 7O0C, preferentially 600C, during 10 to 24 hours, preferably 12 hours, the expected compound being eventually purified;
❖ step D, one prepares a 3β-siloxy-24β-benzoyloxy-5, 20, 22 triene- hydroxycholestane-7-one derivative of formula XIII1
❖ step F, one prepares a 24β-benzoyloxy-3β-hydroxycholestan-7-one derivative of formula XVI1
❖ step H, one prepares the 24-benzoyloxy-7α-hydroxycholestan-3-one of formula I' by oxidation of the hydroxyl substituent in position 3 of the 24β- benzoyloxy-3β,7α-dihydroxycholestane derivative of formula XVIII' obtained in step G, in presence of silver carbonate in an aromatic solvent like toluene, at the reflux temperature of the solvent during 24 hours, the expected compound being eventually purified.
According to the invention, an efficient highly straightforward synthesis of 24-substituted oxy-7-substitutedoxycholestan-3-one of formula I, particularly an efficient highly stereoselective straightforward synthesis of squalamine and trodusquemine precursor of formula I1 is described constituting the shorter and chipper synthesis reported to date.
According to step A of the invention, the chiral derivative of formula Il may be prepared by any well known processes, as for example according to the method describes by Enders et al. (Enders, D. Synlett 1994, 969).
According to one particular embodiment of the invention, the compound of Formula Il is a benzoate derivative, obtained by reacting an hydroxyl derivative of formula XVIII.
Formula XVIII in which R13 represents a vinyl, a methylallyl or an halogeno ethyl group with benzoylchloride in the presence of a base at temperature growing from O0C to 25°C during a minimum of 24 hours, the expected compound being eventually purified.
According to a first alternative of step B of the invention, the 3-siloxy-20- trifluoromethanesulfonyloxy pregnane of formula IV
XIX
H by reacting a pregnenolone of formula VII
❖ step B1-2, one prepares the 3-siloxy-20-trifluoromethanesulfonyloxy pregnenolone derivatives of formula IV by reacting the 3-siloxypregnenolone derivative of formula XIX obtained in step B1-1 with potassium bis(trimethylsilyl)amide in toluene (5 to 15 %, preferentially 10%) and N- phenyltrifluoromethanesulfonimide in THF, under inert atmosphere like argon, at a temperature comprised between-80°C to-70°C, preferentially-78°C, during 15 to 45 minutes, and then warmed to a temperature around 00C, the expected compound being eventually purified.
According to a second alternative of step B of the invention, the 3-siloxy-18-
trifluoromethanesulfonyloxy dehydroepiandrosterone derivatives of formula
❖ step B2-1 , one prepares a 3-siloxydehydroepiandrosterone derivative of formula XXI
R10
R9. R11 sSi
Formula XX
Cl in which R9, R10 and R11 , different or identical, represent a linear, branched alkyl or ether radical, with 1 to 24 carbons, preferentially with 1 to 4 carbons, or an aryl radical (phenyl or substituted phenyl group), under inert atmosphere like
argon or nitrogen, in the presence of a solvent chosen indifferently from tetrahydrofuran (THF) or other ethers, dichloromethane (CH2CI2) or chloroform (CHCI3) or other chlorinated solvent, or dimethylformamide (DMF) or acetonitrile (CH3CN) or toluene or benzene in the presence of a base like pyridine or triethylamine , at a temperature between 20 to 50 0C, during 20 to 30 hours, preferentially in presence of DMF at 25°C for 24 hours, the expected compound being eventually purified; and in
❖ step B2-2 one prepares the 3-siloxy-18-trifluoromethanesulfonyloxy dehydroepiandrosterone derivative of formula III
According to the invention, at each steps, the expected compound is preferentially purified according to well known methods. Preferentially the compounds may be purified by chromatography, for example on a silicagel column or by crystallization.
According to the invention in step D, the oxidation may be performed by well known methods. In one particular embodiment of the invention, the oxidation may be performed for example in the presence of ruthenium trichloride and tert- butylhydroperoxide in cyclohexane, during 20 to 30 hours, preferentially 24 hours, at a temperature comprised between 20 to 300C, preferentially 25 0C.
In another embodiment of the invention, the oxidation of step D may be performed for example in the presence of Na2Cr2O7 in acetone, during 45 to 50 hours, preferentially 48 hours, at a temperature comprised between 35 to 45°C,
preferentially 40 0C, in the presence of sodium sulfite.
Preferentially according to the invention, the oxidation of step D may be performed in the presence of N-hydroxyphtalamide, under a flux of oxygen or air, in the a 50/50 solvent mixture of ethylacetate and acetone, at 600C, during 30 to 40 hours, preferentially 36 hours.
According to the invention, in step F of the process of synthesis the deprotection may be performed in the presence of a fluorhydric acid-based reagent (HF-based reagent), in a solvent chosen from tetrahydrofuran (THF) or other ethers, dichloromethane (CH2CI2) or Chloroform (CHCI3) or other chlorinated solvent, or acetonitrile (CH3CN) or ethyl acetate or diethylether, at temperature raising from-85°C to-65°C, preferentially-78°C, to 250C during a time comprised between 30 to 60 minutes, preferentially 45 minutes.
According to the invention HF-based reagent may be chosen from tetrabutylammoniumfluoride (Bu4)N, tetraalkylarylammoniumfluoride derivative or polymer-bound ammonium fluoride salt, preferentially the HF-based reagent is tetrabutylammoniumfluoride (Bu4)N.
Other characteristics and advantages of the invention will appear in Figure 1 which summarizes the complete way of synthesis of 24β-benzoyloxy-7α- hydroxycholestan-3-one (Formula XXXI) and in the following examples which are illustrations of the invention and which do not limit the invention. Experimental Section
All solvents were purified according to reported procedures, and reagents were used as commercially available. Ethyl acetate and petroleum ether (35-60°C) were purchased from SDS and used without further purification. Column chromatography was performed on SDS silica gel (70-
230 mesh). 1H NMR and 13C NMR spectra were recorded in CDCI3 on a
Bruker AC 300 spectrometer working at 300.00 MHz and 75 MHz, respectively (the usual abbreviations are used: s: singulet, d: doublet, t: triplet, q: quadruplet, m: multiplet). Tetramethylsilane was used as internal standard. All chemical shifts are given in ppm.
Example 1: Example of step B of the invention
Synthesis of 3β-fert-Butyl-dimethylsiloxy-pregnenolone of formula XXIII
XXIII
A solution of 2g of pregnenolone (6.3 10'3 mot) and 474 mg (7 10"3 mol) of imidazole in 10 mL of DMF is treated under argon at room temperature with 1 g of terf-butyldimethylchlorosilane (7 10~3 mol). The reaction mixture is stirred for 48 hours at room temperature, diluted with ethylacetate and washed with water and brine. The organic layer is dried over sodium sulfate, filtered and the solvent removed under reduced pressure. The crude residue is purified by flash chromatography on silicagel (eluent: petroleum ether/ethylacetate 9/1) affording the expected compound of formula XIV as a white solid in 74% yield (2 g).
1H NMR (300 MHz, CDCI3): δ = 0.03 (s, 6H), 0.60 (s, 3H), 0.86-2.24 (m, 34H), 2.50 (m, 1 H), 3.46 (m, 1 H), 5.28 (m, 1 H). - 13C NMR (75 MHz, CDCI3): d =- 4.6, 13.15, 18.17, 19.37, 21.03, 22.79, 24.44, 25.88, 31.46, 31.77, 31.83, 32.01 , 36.55, 37.35, 38.83, 42.74, 43.94, 50.04, 56.92, 63.66, 72.47, 120.80, 141.47, 209.32.
Example 2: Synthesis of 3β-terf-butyl-dimethylsiloxy-20- trifluoromethanesulfonyloxy derivative of formula XXIV
1H NMR (300 MHz, CDCI3): δ = 0.33 (s, 6H), 0.90-95 (m, 3H), 1.17-2.90 (m, 33H), 3.72-3.80 (m, 1 H), 5.23-5.59 (m, 2H). - 13C NMR (75 MHz, CDCI3): d =- 4.61 ,-0.15, 12.65, 18.21 , 19.42, 20.96, 24.09, 25.08, 25.91 , 30.30, 32.04, 32.21 , 36.59, 37.33, 37.90, 42.80, 43.47, 50.05, 54.61 , 55.91 , 72.51 , 104.01 , 120.68, 125.50 (m, CF3), 129.93, 141.66, 158.34.
Example 3: Synthesis of 3β-tert-butyldimethylsiloxy-24β-benzoyloxy- 5,20,22 triene-cholestane derivative of formula XXV
In a typical procedure, 7 mg of Pd(OAc)2 (3.0 10"5 mol) and 18 mg of tri- orf/70-tolylphosphine (6.0 10"5 mol) were mixed under argon in 2 ml_ of DMF and warmed at 600C for 30 minutes. A mixture of 3b-ferf-butyl-dimethylsiloxy-20~
trifluoromethanesulfonyloxy derivative of formula XXIV (133 mg, 2.4 10'4 mol), benzoate derivative of formula XXVI (145 mg, 7.0 10"4 mol)
OCOPh
F~ormula XXVI and triethylamine (56 μl_, 4.0 10"4 mol) dissolved in 4 mL of DMF was then added under argon and stirring was maintained at 600C for 12 hours. After cooling to room temperature, the raction mixture was then diluted with brine and extracted Et.2θ and ethylacetate. The organic phase was washed twice with brine, dried over sodium sulfate, filtered and the solvent removed under reduced pressure. The crude residue was purified by flash chromatography on silicagel (eluent: petroleum ether/ethylacetate 9/1) affording the expected compound of formula XXVI as a white solid in 28% yield (40 mg).
1H NMR (300 MHz, CDCI3): δ = 0.05-0.14 (s, 6H), 0.61-3.46 (m, 44H), 4.83-
4.99 (m, 2H), 5.42 (m, 2H), 7.42-8.17 (m, 6H). - 13C NMR (75 MHz, CDCI3): d =-
3.81 , 0.45, 14.13, 14.89, 20.18, 21.90, 23.61 , 25.69, 26.32, 28.64, 29.87, 30.47, 32.67, 32.92, 37.88, 38.97, 42.68, 44.46, 50.87, 55.69, 70.63, 75.25, 86.70,
123.23, 129.04, 129.32, 130.31 , 131.35, 133.50, 135.31 , 140.55, 166.78.
Example 4: Synthesis of 3β-tert-butyldimethylsiloxy-24β-benzoyloxy- 5, 20, 22 triene-hydroxycholestane-7-one of formula XXVII
t-BUMeoSiO
Compound of formula XVI obtained at the example 3 (40 mg, 6.5 10"5 mol) and N-hydroxyphtalimide (11 mg, 7.1 10"5 mol) were dissolved in ethylacetate-
acetone (6 mL, 1 :1 v/v) and benzoyl peroxide (5 mg) was added to the reaction solution at 600C. Air was bubbled into the reaction mixture with stirring for 48 hours at 600C, and then the reaction mixture was concentrated in vacuo. Dichloromethane (10 mL) was added to the residual oil. The suspension was stirred for 10 minutes and the insoluble material eliminated by filtration over a pad of Celite. The solvent was removed under reduced pressure and the crude residue was purified by flash chromatography on silicagel (eluent: petroleum ether/ethylacetate 95/5 to 9/1) affording the expected compound of formula XXVIII as a white solid in 92% yield (38 mg).
13C NMR (75 MHz, CDCI3): δ =-4.59,-1.00, 13.34, 18.24, 19.41 , 20.87, 23.41 , 25.93, 26.02, 26.38, 29.08, 29.68, 31.76, 31.92, 32.03, 37.14, 37.28, 37.44, 41.90, 42.24, 44.19, 50.17, 54.98, 56.99, 69.85, 71.73, 85.92, 117.15, 121.38, 125.02, 126.87, 129.57, 135.20, 140.85, 166.99, 168.40, 199.21.
Example 5: Synthesis of 3β-tert-butyldimethylsiloxy-24β-benzoyloxy-7- one of formula XXVIII
A solution of 7-oxo compound of formula XXVIII obtained at the example 4 (38 mg, 6.0 10'5 mol) in ethylacetate (10 mL) was stirred at room temperature in the presence of platinum oxide (10 mg) under an atmospher of H2 (3 bars) for 24 hours. The reaction mixture was filtered over Celite, the solvents removed under reduced pressure and the crude residue purified by chromatography on a silicagel column (eluent petroleum ether/ethylacetate 9/1 to 8/2) affording the expected compound of formula XXIX as a white powder in 95% yield (36 mg).
13C NMR (75 MHz, CDCI3): δ =-5.56, 11.78, 12.81 , 18.19, 21.31 , 24.22, 27.41 , 31.52, 36.09, 36.60, 37.42, 37.75, 43.40, 43.88, 49.83, 55.23, 68.63, 73.06, 76.81 , 128.39, 129.53, 129.56, 130.20, 132.84, 165.98, 209.53.
Example 6: Synthesis of 24β-benzoyloxy-3β-hydroxycholestan-7-one of formula XXIX
To a solution of 36 mg (5.7 10"5 mol) of compound of formula XXVIII obtained at the example 5 in 3 mL of anhydrous THF at-78°C was added dropwise 70 μl_ (6.8 10"5 mol) of a 1.0M TBAF solution in THF for 20 min. The reaction mixture was warmed to room temperarture and monitored by TLC analysis. After 40 min, the reaction mixture was quenched by the addition of distilled water (3 mL). The reaction mixture was extracted with ethylacetate, washed with brine, dried over sodium sulfate and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography using petroleum ether/ethylacetate 6/4 to obtain 27 mg (91 % yield) of the expected compound of formula XXIX as a colorless oily material.
13C NMR (75 MHz, CDCI3): δ = 11.21 , 11.80, 18.62, 20.97, 21.75, 21.93, 23.72, 27.96, 31.35, 35.53, 35.74, 35.94, 36.12, 36.24, 39.47, 42.62, 45.84, 48.85, 50.53, 56.10, 71.12, 79.24, 128.01 , 128.25, 129.21 , 129.52, 130.89, 132.58, 166.43, 212.59.
Example 7: Synthesis of 3β, 7α-dihydroxy-24β-benzoyloxycholestane of formula XXX
In a 25 ml_ two necked round flask were placed under argon at-78°C, compound of formula XXIX obtained at the example 6 (27 mg, 5.2 10'5 mol) dissolved in anhydrous THF (10 ml_). L-Selectride (2 equivalents) were slowly added at-78°C and stirred for 5 hours before being quenched by the addition of H2O2 and a solution of NaHCO3 (3 ml_). The residue was dissolved in 10 mL of ethylacetate, washed with brine and dried over MgSO4. After filtration and evaporation of the solvents, the crude residue was purified by chromatography on a silicagel column using petroleum ether/ethylacetate (5/5 to 4/6)) as eluent affording the expected compound of formula XXX in 41% yield.
13C NMR (75 MHz, CDCI3): δ = 11.21 , 11.80, 17.61 , 18.62, 20.97, 21.83, 21.95, 23.72, 27.96, 31.35, 34.90, 35.74, 36.11 , 37.91 , 39.47, 42.62, 45.84, 50.53, 56.10, 71.12, 75.12, 78.93, 128.25, 129.67, 130.89, 132.58, 166.20.
Example 8: Synthesis of 24β-benzoyloxy-7α-hydroxycholestan-3-one of formula XXXI
A suspension of compound of formula XXX obtained at the example 7 (11 mg, 2.1 10~5 mol) and silver carbonate on Celite (25 mg) in toluene (10 mL) was
stirred under argon at reflux overnight. The reaction mixture was filtered through a column of Florisil and the filtrate was concentrated in vacuo. The residue was purified by chromatography on a silicagel column using petroleum ether/ethylacetate (6/4) as eluent affording the expected compound of formula XXXII (9 mg) as a white powder in 82% yield.
13C NMR (75 MHz, CDCI3): δ = 10.72, 11.88, 17.17, 18.79, 22.72, 27.27, 27.91 , 30.89, 35.81 , 36.10, 36.33, 37.52, 38.15, 38.23, 38.79, 39.40, 43.52, 45.33, 49.74, 54.71 , 67.52, 79.23, 128.33, 129.22, 130.03, 133.35, 163.83, 210.95. Example 9: 1-iodo-4-methylpentan-3(S)-ol of formula XXXII
Formula XXXII
A 100 mL three necked flask equipped with an argon inlet, a magnetic stirring bar, an internal thermometer and a septum cap was charged with Ni(acac)2 (258 mg, 1.01 mmole) and cyclooctadiene (242 μL, 2.02 mmole) followed by the chiral isopropyl vinyl alcohol (2 g, 2.02 mmole). The mixture was cooled to-78°C and Et2Zn (6.5 mL, 6.06 mmole) was added dropwise. After completion of the addition, the cooling bath was removed and the reaction mixture was warmed gradually to 400C. It was stirred at this temperature for 5 hours and the excess of Et2Zn was distilled off in vacuo. THF (5 mL) was added to the reaction mixture and was distilled off again. This procedure was repeated twice. The black residue was dissolved in THF (10 mL) and cooled to 78°C. At this temperature, a solution of CuCN.2LiCI prepared from CuCN (1.8 g, 2 10"2 mole) and LiCI (1.68 g, 4 10'2 mole) dissolved in 20 mL of THF was added. The mixture was stirred for 10 minutes at O0C and was cooled back to-78°C. Iodine (15.24 g, 6 10-2 mole) dissolved in THF (20 mL) was added and the reaction mixture was warmed to room temperature and stirred for 12 hours. It was diluted with diethylether (50 mL) and quenched by addition of a saturated aqueous NH4CI (50 mL). The aqueous layer was separated and extracted with diethylether (3x50 mL). The combined organic layer was dried (MgSO4) and filtered and the
solvent was evaporated. The residual oil was purified by flash chromatography (petroleum ether/ethylacetate: 19/1) to afford the expected loldoalcohol XXXII as a pale yellow oil in 54% yield.
13C NMR (75 MHz, CDCI3): δ = 0.9, 16.1 , 32.6, 38.9, 79.6. Example 10: 4-methylpentan-3(S)-benzoate triphenylphosphonium iodide of formula XXXIII
To a solution of 1 g (3 10 mole) of the benzoate iodide derivative issued from compound XXXII in 10 mL of acetonitrile was added 3.93 g (1.5 10"2 mole) of PPh3. The mixture was heated to 8O0C under pressure for 48 hours. After the mixture was cooled to ambient temperature, the solvents were removed in vacuo. The residue was purified by flash chromatography (gradient of 100% Ethylacetate to 100% acetonitrile then methanol). 13C NMR (75 MHz, CDCI3): δ = 16.3, 17.0, 30.1 , 36.2, 85.3, 129.1-132.8,
167,0.
Example 11 : synthesis of 3β-tert-butyldimethylsiloxy-24β-benzoyloxy-5,20 diene-cholestane of formula XXXIV
Sodium hydride (2.01 mmole) and phosphonium salt XXXIII were added to 25 mL of dry THF. The 3β-tertbutyldimethylsiloxy-pregnenolone of formula XXIII was added and the mixture was refluxed for 12 hours. The reaction mixture was partioned between ether and water, extracted with ether and dried over magnesium sulfate. The crude residue is purified by flash chromatography on silicagel (eluent: ethylacete/petroleum ether) to afford the expected derivative in 69% yield.
Synthesis of derivative of formula XXI from derivative XXXIV was realized according to the methodology described in example 4 to example 8.
Claims
1) Process of synthesis of 24-substituted oxy-7-substitutedoxycholestan-3- one of formula I
0R3
R7 Formula II wherein
R3 represents an ester or an ether group
R4 represents a vinyl group, methylallyl group or a diethylphosphonium group of formula Ua, lib or Mc
Formula Ha or Formula lib Or Formula Hc and R5, R6, R7 and R8 represent an alkyl, aryl, halide or amine group ❖ step B, one prepares a 3-siloxy-18-trifluoromethanesulfonyloxy dehydroepiandrosterone derivatives of formula III OTf 
Formula III
or a 3-siloxy-20-trifluoromethanesulfonyloxy pregnane derivative of formula IV
Formula IV
in which R9, R10 and R11 , different or identical, represent a linear or branched alkyl or ether radical, with 1 to 24 carbons, preferentially with 1 to 4 carbons, or an aryl radical (phenyl or substituted phenyl group); or a 3-substituted oxy pregnenolone of formula V, or a 3-substituted oxy-7-oxy pregnane derivatives of formula Vl or VII.
Formula V
Formula VI 
Formula VII
wherein R represents an ether, silyl, substituted silyl or ester group;
❖ step C, one prepares a pregnane derivative of formula VIII or IX
R9RI0Rl lS 
ιO 
by reacting the substited oxy derivative Ha or lib obtained in step A with the activated pregnane derivatives (formula III-IV) obtained in step B, in the presence of a first catalyst and a first ligand, under inert atmosphere, in a first polar solvent and in the presence of a first base, at a temperature comprised between 25°C to 95°C1, preferentially between 5O0C to 7O0C, most preferentially 60°C, the expected compound being eventually purified; or one prepares a pregnane derivative of Formula X, Xl or XII
1 Est envisageable 
pregnane derivatives (formula V-VII) obtained in step B, in the presence of a second base, under inert atmosphere, in a second polar solvent at a temperature comprised between 0 to 250C, preferentially 00C, the expected compound being eventually purified;
❖ step D, one prepares a 3-siloxy-24-substituted oxy-7 one pregnane derivatives of formula XIII-XIV or a 3-substituted-24-substituted oxy-7 one pregnane derivatives of Formula Xl
R9R10Rl 
by oxidizing derivatives of formula VIII orX obtained in step C, the expected compound being eventually purified; ❖ step E, one prepares a 3-substituted oxy-24-substituted-7-one derivative of formula XV
❖ step F, one prepares a 24-substituted oxy-3-hydroxycholestan-7-one derivative of formula XVI 
by deprotection of the 3-substituted-24-substituted-7-one derivative of formula XV obtained in step E preferentially in presence of fluoride ions, the expected compound being eventually purified;
❖ step G, one prepares a 24-substituted oxy-3,7-dihydroxycholestane derivative of formula XVII
❖ step H, one prepares the 24-substituted oxy-7-hydroxycholestan-3- one of formula I by oxidation of the hydroxyl substituant in position 3 of the 24- substituted-3,7-dihydroxycholestane derivative of formula XVII obtained in step
G, in presence of silver carbonate in a solvent, at the reflux temperature of the solvent, the expected compound being eventually purified.
2.) Process of synthesis according to claim 1 , wherein in step C the first catalyst is Palladium acetate [Pd(OAc)2] or Palladium salt like Pd(OAc)2.
3.)
Process of synthesis according to anyone of claims 1 or 2, wherein in step C the first ligand is a phosphine, for example triphenylphosphine, tributylphosphine, tri fert-butyl phosphine and preferentially tύ-ortho- tolylphosphine.
4.) Process of synthesis according to anyone of claims 1 to 3, wherein in step C the first polar solvent is dimethylformamide (DMF), dimethylacetamide or hexamethylphosphoramide (HMPA).
5.) Process of synthesis according to anyone of claims 1 to 4, wherein in step C the first base is an aliphatic tertiary amine like triethylamine or pyridine, preferentially pyridine.
6.) Process of synthesis according to anyone of claims 1 to 5, wherein in step C the inert atmosphere is argon or nitrogen.
7.) Process of synthesis according to anyone of claims 1 to 6, wherein in step C the second polar solvent is tetrahydrofurane, dioxane or diethylether.
8.) Process of synthesis according to anyone of claims 1 to 7, wherein in step C the second base is sodium hydride, potassium hydride, potassium tert butylate, preferentially sodium hydride, lithium hexamethyldisilazane, butyllithium, sec-butyllithium or tert-butyllithium.
9.) Process of synthesis according to anyone of claims 1 to 8, wherein step C is performed during 1 to 24 hours, preferably 12 hours.
10.) Process of synthesis according to anyone of claims 1 to 9, wherein in step E the catalyst is a platinum oxide catalyst.
11.) Process of synthesis according to anyone of claims 1 to 10, wherein in step E the polar solvent is DMF, dimethylacetamide, THF, dioxame or HMPA.
12.) Process of synthesis according to anyone of claims 1 to 11 , wherein step E is performed at a pressure comprised between 1 to 100 bars, preferably 3 bars.
13.) Process of synthesis according to anyone of claims 1 to 12, wherein step E is performed during 1 to 30 hours, preferably 24 hours.
14.) Process of synthesis according to anyone of claims 1 to 13, wherein step G the stereoselective reducing hydride reagent is - either potassium tri-sec-butylborohydride (L-selectride®) to obtain a 7α dihydrocholestane; or Iithium/NH3 to obtain a 7β dihydrocholestane.
15.) Process of synthesis according to anyone of claims 1 to 14, wherein step H the solvent is toluene, benzene, hexane, heptane or cyclohexane.
16.) Process of synthesis according to anyone of claims 1 to 15, to prepare 24β-benzoyloxy-7α-hydroxycholestan-3-one of formula I1
17.) Process of synthesis according to claim 16, wherein in step A, one prepares a benzoate derivative of formula Il
OCOPh
18.) Process of synthesis according to anyone claims 16 or 17, wherein in step B one prepares a 3β~siloxy-18- trifluoromethanesulfonyloxydehydroepiandrosterone derivatives of formula III
19.) Process of synthesis according to anyone claims 16 to 18, wherein in step C one prepares a 3β-siloxy-24b-benzoyloxy-5,20,22 triene- hydroxycholestane derivative of formula VIII1
20.) Process of synthesis according to claim 19, wherein the phosphine ligand is triphenylphosphine, tributylphosphine, tri te/f-butyl phosphine and preferentially tri-ort/70-tolylphosphine.
21.) Process of synthesis according to anyone claims 19 or 20, wherein the ratio Pd/Ligand is 1 :2.
22.) Process of synthesis according to anyone claims 19 to 21 , wherein the inert atmosphere is argon or nitrogen.
23.) Process of synthesis according to anyone claims 19 to 22, wherein the polar solvent is DMF or dimethylacetamide.
24.) Process of synthesis according to anyone claims 19 to 23, wherein the base is triethylamine or pyridine.
25.) Process of synthesis according to anyone claims 19 to 24, wherein step C is performed at a temperature comprised between 500C to 7O0C, preferentially 600C
26.) Process of synthesis according to anyone claims 19 to 25, wherein step C is performed during 10 to 24 hours, preferably 12 hours.
27.) Process of synthesis according to anyone claims 16 to 26, wherein in step E the pressure is comprised between 2 to 10 bars, preferably 3 bars.
28.) Process of synthesis according to anyone claims 16 to 27, wherein in step E the hydrogenation is performed during 20 to 30 hours, preferably 24 hours.
29.) Process of synthesis according to anyone claims 16 to 28, wherein in step E the hydrogenation is performed at a temperature comprised between 20 to 30 °C, preferably 250C.
30.) Process of synthesis according to anyone claims 16 to 29, wherein in step E, the reduction is performed at a temperature raising from-78°C to room temperature (25°C).
31.) Process of synthesis according to anyone claims 16 to 30, wherein in step E, the reduction is performed during a minimum of 5 hours.
32.) Process of synthesis according to anyone claims 1 to 31 , wherein in step A, the compound of Formula Il is a benzoate derivative, obtained by reacting an hydroxyl derivative of formula XVIII
Formula XVIII in which R13 represents a vinyl, a methylallyl or an halogeno ethyl group with benzoylchloride in the presence of a base at temperature growing from 00C to 25°C during a minimum of 24 hours, the expected compound being eventually purified.
33.) Process of synthesis according to anyone claims 1 to 32, wherein In step B, the 3-siloxy-20-trifluoromethanesulfonyloxy pregnane of formula IV
+ step B1-1 , one prepares a 3-siloxypregnenolone derivative of formula
XIX
H by reacting a pregnenolone of formula VII
+ step B1-2, one prepares the 3-siloxy-20-trifluoromethanesulfonyloxy pregnenolone derivatives of formula IV by reacting the 3-siloxypregnenolone derivative of formula XIX obtained in step B 1-1 with potassium bis(trimethylsilyl)amide in toluene (5 to 15 %, preferentially 10%) and N- phenyltrifluoromethanesulfonimide in THF, under inert atmosphere like argon, at a temperature comprised between-80°C to-70°C, preferentially-78°C, during 15 to 45 minutes, and then warmed to a temperature around 00C, the expected compound being eventually purified. 33.) Process of synthesis according to anyone claims 1 to 32, wherein In step B, the 3-siloxy-18-trifluoromethanesulfonyloxy dehydroepiandrosterone derivatives of formula III
R10
R9 R11
Si
Formula XX
Cl in which R9, R10 and R11 , different or identical, represent a linear, branched alkyl or ether radical, with 1 to 24 carbons, preferentially with 1 to 4 carbons, or an aryl radical (phenyl or substituted phenyl group), under inert atmosphere, in the presence of a solvent, in the presence of a base, at a temperature between 20 to 50 0C, during 20 to 30 hours, preferentially in presence of DMF at 25°C for 24 hours, the expected compound being eventually purified; and in
+ step B2-2 one prepares the 3-siloxy-18-trifluoromethanesulfonyloxy dehydroepiandrosterone derivative of formula III
34.) Process of synthesis according to anyone claims 32 or 33, wherein in step B1-1 or B2-1 the inert atmosphere is argon or nitrogen.
35.) Process of synthesis according to anyone claims 32 to 35, wherein in step B1-1 or B2-1 , the solvent is chosen indifferently from tetrahydrofuran (THF) or other ethers, dichloromethane (CH2CI2) or chloroform (CHCI3) or other chlorinated solvent, or dimethylformamide (DMF) or acetonitrile (CH3CN) or toluene or benzene.
36.) Process of synthesis according to anyone claims 32 to 35, wherein in step B1-1 or B2-1 , the base is pyridine or triethylamine
37.) Process of synthesis according to anyone claims 32 to 36, wherein step B1-1 or B2-1 is performed at a temperature between 20 to 50 0C.
38.) Process of synthesis according to anyone claims 32 to 37, wherein step B1-1 or B2-1 is performed during 20 to 30 hours.
39.) Process of synthesis according to anyone claims 32 to 38, wherein step B1-1 or B2-1 is performed in presence of DMF at 25°C for 24 hours.
40.) Process of synthesis according to anyone claims 1 to 39, wherein in step D, the oxidation is performed in the presence of ruthenium trichloride and terf-butylhydroperoxide in cyclohexane, during 20 to 30 hours, preferentially 24 hours, at a temperature comprised between 20 to 3O0C, preferentially 25 0C.
41.) Process of synthesis according to anyone claims 1 to 39, wherein in step D, the oxidation is performed in the presence of Na2Cr2O7 in acetone, during 45 to 50 hours, preferentially 48 hours, at a temperature comprised between 35 to 450C, preferentially 40 0C, in the presence of sodium sulfite.
42.) Process of synthesis according to anyone claims 1 to 39, wherein in step D, the oxidation is performed in the presence of N-hydroxyphtalamide, under a flux of oxygen or air, in the a 50/50 solvent mixture of ethylacetate and acetone, at 6O0C, during 30 to 40 hours, preferentially 36 hours.
43.) Process of synthesis according to anyone claims 1 to 42, wherein in step F, the deprotection is performed in the presence of a fluorhydric acid-based reagent (HF-based reagent) or polymer-bound ammonium fluoride salt, in a solvent.
44.) Process of synthesis according to claim 43, wherein fluorhydric acid- based reagent (HF-based reagent) is chosen from tetrabutylammoniumfluoride (Bu4)N, tetraalkylarylammoniumfluoride derivative; preferentially the HF-based reagent is tetrabutylammoniumfluoride (Bu4)N.
45.) Process of synthesis according to anyone claims 43 to 45, wherein the solvent is chosen from tetrahydrofuran (THF) or other ethers, dichloromethane (CH2CI2) or Chloroform (CHCI3) or other chlorinated solvent, or acetonitrile (CH3CN) or ethyl acetate or diethylether.
46.) Process of synthesis according to anyone claims 43 to 45, wherein step F is performed at temperature raising from-85°C to-65°C, preferentially- 78°C, to 25°C.
47.) Process of synthesis according to anyone claims 43 to 46, wherein step F is performed during a time comprised between 30 to 60 minutes, preferentially 45 minutes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90685607P | 2007-03-14 | 2007-03-14 | |
| US60/906,856 | 2007-03-14 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008110941A2 true WO2008110941A2 (en) | 2008-09-18 |
| WO2008110941A3 WO2008110941A3 (en) | 2009-05-22 |
Family
ID=39760170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2008/001730 WO2008110941A2 (en) | 2007-03-14 | 2008-03-14 | New process of synthesis of a squalamine and/or trodusquemine precursor |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008110941A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014100679A1 (en) * | 2012-12-20 | 2014-06-26 | Mount Desert Island Biological Laboratory | Stimulation and enhancement of regeneration of tissues |
| CN105377871A (en) * | 2013-06-28 | 2016-03-02 | 台湾神隆股份有限公司 | Process for the preparation of abiraterone and intermediates thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994019366A1 (en) * | 1993-02-26 | 1994-09-01 | Magainin Pharmaceuticals Inc. | Chemical synthesis of squalamine |
-
2008
- 2008-03-14 WO PCT/IB2008/001730 patent/WO2008110941A2/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994019366A1 (en) * | 1993-02-26 | 1994-09-01 | Magainin Pharmaceuticals Inc. | Chemical synthesis of squalamine |
Non-Patent Citations (4)
| Title |
|---|
| MORIARTY R M ET AL: "SYNTHESIS OF SQUALAMINE.A STEROIDAL ANTIBIOTIC FROM THE SHARK" TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, vol. 35, no. 44, 31 October 1994 (1994-10-31), pages 8103-8106, XP000572370 ISSN: 0040-4039 cited in the application * |
| OKUMURA, KAZUO ET AL: "Formal synthesis of squalamine from desmosterol" CHEMICAL & PHARMACEUTICAL BULLETIN , 51(10), 1177-1182 CODEN: CPBTAL; ISSN: 0009-2363, 2003, XP002516638 * |
| ORSINI F ET AL: "Pd(0)-MEDIATED CROSS-COUPLING OF REFORMATSKY REAGENTS WITH VINYL- AND ARYL TRIFLATES" SYNTHETIC COMMUNICATIONS, TAYLOR & FRANCIS, PHILADELPHIA, PA, vol. 17, no. 12, 1 January 1987 (1987-01-01), pages 1389-1402, XP003020475 ISSN: 0039-7911 * |
| TAKAGI, JUN; TAKAHASHI, KOU; ISHIYAMA, TATSUO; MIYAURA, NORIO: "Palladium-Catalyzed Cross-Coupling Reaction of Bis(pinacolato)diboron with 1-Alkenyl Halides or Triflates: Convenient Synthesis of Unsymmetrical 1,3-Dienes via the Borylation-Coupling Sequence" JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 124, no. 27, 2002, pages 8001-8006, XP002516639 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014100679A1 (en) * | 2012-12-20 | 2014-06-26 | Mount Desert Island Biological Laboratory | Stimulation and enhancement of regeneration of tissues |
| US9504700B2 (en) | 2012-12-20 | 2016-11-29 | Mount Desert Island Biological Laboratory | Methods and compositions for stimulation and enhancement of regeneration of tissues |
| CN105377871A (en) * | 2013-06-28 | 2016-03-02 | 台湾神隆股份有限公司 | Process for the preparation of abiraterone and intermediates thereof |
| JP2016523889A (en) * | 2013-06-28 | 2016-08-12 | サイノファーム タイワン，リミティド | Preparation method of abiraterone and its intermediate |
| US9556218B2 (en) | 2013-06-28 | 2017-01-31 | Scinopharm Taiwan, Ltd. | Process for the preparation of abiraterone and intermediates thereof |
| EP3013848A4 (en) * | 2013-06-28 | 2017-03-15 | Scinopharm Taiwan, Ltd. | Process for the preparation of abiraterone and intermediates thereof |
| CN105377871B (en) * | 2013-06-28 | 2017-06-06 | 台湾神隆股份有限公司 | The preparation method of abiraterone and its intermediate |
| AU2014300639B2 (en) * | 2013-06-28 | 2018-03-01 | Scinopharm Taiwan, Ltd. | Process for the preparation of abiraterone and intermediates thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008110941A3 (en) | 2009-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2648845B2 (en) | Method for producing 19-nor-vitamin D compound and intermediate used therefor | |
| CA1308095C (en) | 11.beta.-ARYLESTRADINENES, THE PRODUCTION, AND PHARMACEUTICAL PREPARATIONS CONTAINING SAME | |
| DK2714710T3 (en) | A process for the preparation of intermediates estetrol | |
| AU2001253427B2 (en) | A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group | |
| JPH0369919B2 (en) | ||
| AU2011343615A1 (en) | Methods and compounds for preparing 3alpha-oxygen substituted steroids | |
| AU2001253427A1 (en) | A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group | |
| EP2266998B1 (en) | Process for obtaining 17-spirolactones in steroids | |
| KR860001469B1 (en) | 17-(isocyano-sulfonylmthylene)-steroids 17-(formamido-sulfonylmethylene)-steroids and their preparation | |
| US7491712B1 (en) | Process for preparation of paricalcitol and intermediates thereof | |
| HU182607B (en) | Process for preparing pregnane-21-aldehydes | |
| WO2008110941A2 (en) | New process of synthesis of a squalamine and/or trodusquemine precursor | |
| US4267106A (en) | New process for the preparation 17β-hydroxy-3-oxo-17α-pregnene and pregnadiene-21-carboxylic acid γ-lactones | |
| AU646342B2 (en) | New substituted 16-methyl steroid derivatives of pregna-1,4-diene-3,20-dione, their preparation, their use in the preparation of 16-methylene steroids and new intermediates | |
| WO1991018918A1 (en) | PROCESS FOR PRODUCING 10β-H-STEROIDS | |
| US20040127702A1 (en) | Novel crystal form | |
| EP0591268A1 (en) | Method for the preparation of 6-methylene steroids | |
| EP0175540B1 (en) | 20-silyl ether steroids, and preparing 17-hydroxy-20-keto steroids | |
| EP0378563B1 (en) | Conversion of steroidal 17-cyanohydrins to corticoids | |
| JP3066047B2 (en) | New vitamin D (lower 3) derivatives | |
| MX2012009251A (en) | A process for introducing a double bond into position 15,16 of a steroid. | |
| Mason | Exploring cyclizations of planar chiral η-4 iron (0) tricarbonyl diene complexes | |
| CA1247079A (en) | Steroids and process for preparing same | |
| DE4301461A1 (en) | Process for the preparation of derivatives of oestra-1,3,5(10),14-tetraene-3,17 alpha -diol | |
| JP3759636B2 (en) | Pregnane derivative and process for producing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08762987 Country of ref document: EP Kind code of ref document: A2 |